Moors & Cabot’s Moderna MRNA Stock Holding History

Moors & Cabot’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300	Closed	-$1.65K	–	912
2022 Q4	$1.65K	Buy	+300	New	+$49.1K	﹤0.01%	847

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Moors & Cabot's MRNA Position: Q1 2026 in Review

Moors & Cabot reduced its Moderna (MRNA) stake by 40% in Q1 2026, selling an estimated $306K and leaving 9,916 shares worth $504K. The position accounts for 0.02% of the portfolio, ranked #550.

Moors & Cabot first reported a position in MRNA in Q2 2019 and has held it in 28 quarters since. The position peaked at $15M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Moors & Cabot held 9,916 shares of Moderna worth $504K as of Q1 2026.
Moors & Cabot sold 6,556 Moderna shares in Q1 2026, an estimated $306K.
Moderna made up 0.02% of Moors & Cabot's portfolio in Q1 2026, its #550 holding.
Moors & Cabot first reported a position in Moderna in Q2 2019 and has held it in 28 quarters since.
Moors & Cabot's Moderna position peaked at $15M in Q3 2021.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.